论文部分内容阅读
目的:观察HBsAg致敏患者自体外周血单个核细胞(PBMC)来源的树突状细胞(DC)疫苗(简称抗HBV-DC)治疗慢性HBV携带者的临床效果。方法:15例HBeAg阳性和5例HBeAg阴性的慢性HBV携带者接受临床试验。取外周静脉血25ml,用密度梯度离心及贴壁法获得单核细胞,以粒细胞-巨噬细胞集落刺激因子(GM-CSF)和白细胞介素4(IL-4)诱导扩增出DC,并予HBsAg致敏DC。第7天收获DC静脉回输,1次/周,共4次。治疗前后检测HBV标志物定量、HBV-DNA定量及肝功能。结果:治愈1例,好转18例,无效1例,总有效率为95%(19/20),治愈率5%(1/20)。结论:抗HBV-DC静脉回输可有效地抑制慢性HBV携带者的病毒复制,降低并清除病毒抗原,促进HBeAg/HBeAb的血清学转换,是一种安全、有效的治疗慢性HBV携带的方法。
Objective: To observe the clinical efficacy of autologous peripheral blood mononuclear cells (PBMC) -derived dendritic cells (DC) vaccine (anti-HBV-DC) in the treatment of chronic HBV carriers in HBsAg-sensitized patients. METHODS: Fifteen HBeAg-positive and five HBeAg-negative chronic HBV carriers underwent clinical trials. Take 25ml of peripheral venous blood, mononuclear cells were obtained by density gradient centrifugation and adherence method, DCs were induced by GM-CSF and IL-4, And to HBsAg-sensitized DC. On the 7th day, the DC vein was harvested, once / week for 4 times. Before and after treatment to detect HBV markers quantitative, HBV-DNA quantitative and liver function. Results: 1 case cured, 18 cases improved and 1 case ineffective. The total effective rate was 95% (19/20) and the cure rate was 5% (1/20). Conclusion: The anti-HBV-DC venous transfusion can effectively inhibit the virus replication in chronic HBV carriers, reduce and eliminate viral antigens and promote the seroconversion of HBeAg / HBeAb. It is a safe and effective method to treat chronic HBV carriers.